Advertisement
U.S. markets close in 4 hours 26 minutes
  • S&P 500

    5,254.15
    +5.66 (+0.11%)
     
  • Dow 30

    39,773.53
    +13.45 (+0.03%)
     
  • Nasdaq

    16,405.52
    +6.00 (+0.04%)
     
  • Russell 2000

    2,127.32
    +12.97 (+0.61%)
     
  • Crude Oil

    82.58
    +1.23 (+1.51%)
     
  • Gold

    2,236.40
    +23.70 (+1.07%)
     
  • Silver

    25.00
    +0.25 (+1.00%)
     
  • EUR/USD

    1.0805
    -0.0025 (-0.23%)
     
  • 10-Yr Bond

    4.1910
    -0.0050 (-0.12%)
     
  • GBP/USD

    1.2635
    -0.0003 (-0.02%)
     
  • USD/JPY

    151.2010
    -0.0450 (-0.03%)
     
  • Bitcoin USD

    71,187.34
    +2,169.88 (+3.14%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,970.01
    +38.03 (+0.48%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Implant Sciences to Host Conference Call Wednesday, January 16th at 1:30 pm EST

WILMINGTON, MA--(Marketwire - Jan 16, 2013) - Implant Sciences Corporation (OTCQB: IMSC) a high technology supplier of systems and sensors for homeland security markets, will be hosting a conference call today, January 16th, 2013, at 1:30 PM EST to provide an update to our investors on recent developments.

Company Conference Call

Management will host a conference call on Wednesday, January 16, 2013 at 1:30 PM Eastern time to provide an update to investors. Following the Company's prepared remarks there will be a Q&A session. The call can be accessed by interested parties by dialing: 800-599-9795 within the U.S. or 617-786-2905 outside the U.S. and entering passcode 81810618. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins. A replay of the conference call will be available approximately two hours after the call for one month by dialing: 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and entering passcode 64281079. The conference call will also be available live over the Internet at the investor relations section of Implant Sciences' website at www.implantsciences.com. A replay of the webcast will be available for one month after the call.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Advertisement